ALCAM and prostate carcinoma: Importantly, upregulated CD166 expression and expansion of CD166hi cells correlate with Pten null CRPC progression as well as human CRPC development, although genetic deletion of CD166 does not interfere with normal murine prostate development or Pten null prostate cancer progression.